Addressing the dense stromal barrier, it reveals that the interaction between cancer cell NRG1 and CAF ERBB3 activates the STAT3 pathway, leading to the “ERBB3 inhibitor + stromal metalloproteinase activator” strategy. The gene discussed is ERBB3; the disease is cancer.